MAPT and Alzheimer disease: Although there exist reliable fluid biomarkers for AD (Bălaşa et al., 2020), the differential diagnosis for FTLD subtypes based on CSF or blood biomarkers of tau or TDP-43 remains limited and inconclusive (Vijverberg et al., 2017).